Negative / Null Result ReportOpen accessMedicine
Obbina Abani, Ali Abbas, Fatima Abbas et al. · 2021 · The Lancet
BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care al
View details →DOI: 10.1016/s0140-6736(21)00897-7Cited by 521 Negative / Null Result ReportOpen accessMedicine
Dan Frampton, Tommy Rampling, Aidan Cross et al. · 2021 · The Lancet Infectious Diseases
BACKGROUND: Emergence of variants with specific mutations in key epitopes in the spike protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of monoclonal antibodies. We aimed to describe the emergence of…
View details →DOI: 10.1016/s1473-3099(21)00170-5Cited by 456 Negative / Null Result ReportOpen accessMedicine
Ming Yang, Shuo Chen, Bo Huang et al. · 2020 · European Urology Focus
BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), involves multiple organs. Testicular involvement is largely unknown. OBJECTIVE: To determine the pathological changes…
View details →DOI: 10.1016/j.euf.2020.05.009Cited by 444 Negative / Null Result ReportOpen accessMedicine
Lucy van Dorp, Damien Richard, Cedric Tan et al. · 2020 · Nature Communications
COVID-19 is caused by the coronavirus SARS-CoV-2, which jumped into the human population in late 2019 from a currently uncharacterised animal reservoir. Due to this recent association with humans, SARS-CoV-2 may not yet be fully adapted to its human host. This has led to speculations that SARS-CoV-2 may be evolving towards higher transmissibility. The most plausible mutations under putative natural selection are those which have emerged repeatedly and independently (homoplasies). Here, we formally test whether any homoplasies observed in SARS-CoV-2 to date are significantly associated with inc
View details →DOI: 10.1038/s41467-020-19818-2Cited by 317 Negative / Null Result ReportMedicine
Shitao Rao, Alexandria Lau, Hon‐Cheong So · 2020 · Diabetes Care
OBJECTIVE COVID-19 has become a major public health problem. There is good evidence that ACE2 is a receptor for SARS-CoV-2, and high expression of ACE2 may increase susceptibility to infection. We aimed to explore risk factors affecting…
View details →DOI: 10.2337/dc20-0643Cited by 258 Negative / Null Result ReportOpen accessMedicine
Donna R. Rivera, Solange Peters, Orestis A. Panagiotou et al. · 2020 · Cancer Discovery
Abstract Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic…
View details →DOI: 10.1158/2159-8290.cd-20-0941Cited by 138 Negative / Null Result ReportOpen accessSocial Sciences
Sarah Kreps, Nabarun Dasgupta, John S. Brownstein et al. · 2021 · npj Vaccines
While efficacious vaccines have been developed to inoculate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; also known as COVID-19), public vaccine hesitancy could still undermine efforts to combat the pandemic. Employing a survey of 1096 adult Americans recruited via the Lucid platform, we examined the relationships between vaccine attributes, proposed policy interventions such as financial incentives, and misinformation on public vaccination preferences. Higher degrees of vaccine efficacy significantly increased individuals' willingness to receive a COVID-19 vaccine, whi
View details →DOI: 10.1038/s41541-021-00335-2Cited by 128 Negative / Null Result ReportOpen accessMedicine
Karin Welén, Ebba Rosendal, Magnus Gisslén et al. · 2021 · European Urology
BACKGROUND: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response. OBJECTIVE: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on…
View details →DOI: 10.1016/j.eururo.2021.12.013Cited by 57 Negative / Null Result ReportOpen accessMedicine
Sara Galimberti, Mario Petrini, Claudia Baratè et al. · 2020 · Frontiers in Oncology
SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1. Very few cases of COVID-19 have been reported in Ph+ ALL and in CML Italian cohorts; authors suggested that this low rate of infections might depend f
View details →DOI: 10.3389/fonc.2020.01428Cited by 47 Negative / Null Result ReportMedicine
Larisa I. Labzin, Keng Yih Chew, Kathrin Eschke et al. · 2023 · Science Signaling
Macrophages are key cellular contributors to the pathogenesis of COVID-19, the disease caused by the virus SARS-CoV-2. The SARS-CoV-2 entry receptor ACE2 is present only on a subset of macrophages at sites of SARS-CoV-2 infection in…
View details →DOI: 10.1126/scisignal.abq1366Cited by 46 Negative / Null Result Report
Austin Clyde, Xuefeng Liu, Thomas Brettin et al. · 2023 · Scientific Reports
Abstract Protein-ligand docking is a computational method for identifying drug leads. The method is capable of narrowing a vast library of compounds down to a tractable size for downstream simulation or experimental testing and is widely…
View details →DOI: 10.1038/s41598-023-28785-9Cited by 28 Negative / Null Result ReportOpen accessMedicine
Carlos Farkas, Andy Mella, Maxime Turgeon et al. · 2021 · Frontiers in Microbiology
An unprecedented amount of SARS-CoV-2 sequencing has been performed, however, novel bioinformatic tools to cope with and process these large datasets is needed. Here, we have devised a bioinformatic pipeline that inputs SARS-CoV-2 genome sequencing in FASTA/FASTQ format and outputs a single Variant Calling Format file that can be processed to obtain variant annotations and perform downstream population genetic testing. As proof of concept, we have analyzed over 229,000 SARS-CoV-2 viral sequences up until November 30, 2020. We have identified over 39,000 variants worldwide with increased polymo
View details →DOI: 10.3389/fmicb.2021.665041Cited by 26 Negative / Null Result ReportOpen accessMedicine
Arthur Wickenhagen, Meaghan Flagg, Julia R. Port et al. · 2025 · Nature Communications
The emergence of the Omicron lineage represented a major genetic drift in SARS-CoV-2 evolution. This was associated with phenotypic changes including evasion of pre-existing immunity and decreased disease severity. Continuous evolution within the Omicron lineage raised concerns of potential increased transmissibility and/or disease severity. To address this, we evaluate the fitness and pathogenesis of contemporary Omicron variants XBB.1.5, XBB.1.16, EG.5.1, and JN.1 in the upper (URT) and lower respiratory tract (LRT). We compare in vivo infection in Syrian hamsters with infection in primary h
View details →DOI: 10.1038/s41467-025-55938-3Cited by 24 Negative / Null Result ReportOpen accessMedicine
Santiago Moreno, Bernardino Alcázar-Navarrete, Carlos Dueñas et al. · 2022 · Drug Design Development and Therapy
The aim of this report is to review the literature and shed light on the uncertainties surrounding the use of antiviral agents in general and remdesivir in COVID-19 patients. This review evaluated a battery of antiviral compounds and their…
View details →DOI: 10.2147/dddt.s356951Cited by 20 Negative / Null Result ReportOpen accessMedicine
Dipender Gill, Marios Arvanitis, Paul Carter et al. · 2020 · Royal Society Open Science
Angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 have been implicated in cell entry for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). The expression of ACE2 and TMPRSS2 in the lung epithelium might have implications for the risk of SARS-CoV-2 infection and severity of COVID-19. We use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to investigate whether these exposures affect lung ACE2 and TMPRSS2 gene expression and circ
View details →DOI: 10.1098/rsos.200958Cited by 19 Negative / Null Result Report
Ian G Barr, Cleve Rynehart, Paul Whitney et al. · 2020 · Eurosurveillance
The advent of COVID-19, has posed a risk that human respiratory samples containing human influenza viruses may also contain SARS-CoV-2. This potential risk may lead to SARS-CoV-2 contaminating conventional influenza vaccine production…
View details →DOI: 10.2807/1560-7917.es.2020.25.25.2001122Cited by 19 Negative / Null Result ReportOpen accessMedicine
Shao-rui Hao, Yan Ren, Shan-yan Zhang et al. · 2020 · Journal of Zhejiang University SCIENCE B
BACKGROUND: Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a…
View details →DOI: 10.1631/jzus.b2000211Cited by 17 Negative / Null Result ReportOpen accessMedicine
Miguel Górgolas Hernández-Mora, Alfonso Cabello, Laura Prieto-Pérez et al. · 2020 · International Journal of Infectious Diseases
INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory…
View details →DOI: 10.1016/j.ijid.2020.10.045Cited by 16 Negative / Null Result Report
Bjoern Zante, Katja Erne, Marie-Madlen Jeitziner · 2022 · Scientific Reports
Abstract To help reduce the spread of the SARS-CoV-2 virus during the COVID-19 pandemic, ICU visits were banned or restricted. Therefore, family-centered care as usually practiced was not feasible Video calls were recommended to meet…
View details →DOI: 10.1038/s41598-022-18616-8Cited by 15 Negative / Null Result ReportOpen accessMedicine
Daigo Nakazawa, Yohei Takeda, Masatoshi Kanda et al. · 2023 · Cell Death Discovery
Acute kidney injury (AKI) is a common and severe complication of the coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly affects the glomerular and tubular epithelial cells to induce AKI; however, its pathophysiology remains unclear. Here, we explored the underlying mechanisms and therapeutic targets of renal involvement in COVID-19. We developed an in vitro human kidney cellular model, including immortalized tubular epithelial and endothelial cell lines, demonstrating that SARS-CoV-2 directly triggers cell death. To identify the molecular
View details →DOI: 10.1038/s41420-023-01584-xCited by 13 Negative / Null Result ReportOpen accessMedicine
Marwah Karim, Manjari Mishra, Chieh‐Wen Lo et al. · 2025 · Nature Communications
In search for broad-spectrum antivirals, we discover a small molecule inhibitor, RMC-113, that potently suppresses the replication of multiple RNA viruses including SARS-CoV-2 in human lung organoids. We demonstrate selective inhibition of…
View details →DOI: 10.1038/s41467-025-61759-1Cited by 10 Negative / Null Result ReportOpen accessMedicine
Dayoung Seo, Yangsean Choi, Eunseon Jeong et al. · 2025 · Nature Communications
Although brain alterations have been reported in post-acute sequelae of SARS-CoV-2 (PASC), their prevalence and relationship to neurodegeneration remain unclear. We analyzed blood proteins and brain MRI from individuals approximately one…
View details →DOI: 10.1038/s41467-025-65597-zCited by 9 Negative / Null Result ReportOpen accessMedicine
Shailesh D. Pawar, Sadhana S. Kode, Sachin S. Keng et al. · 2022 · The Indian Journal of Medical Research
Background & objectives Polio, measles, rubella, influenza and rotavirus surveillance programmes are of great public health importance globally. Virus isolation using cell culture is an integral part of such programmes. Possibility of…
View details →DOI: 10.4103/ijmr.ijmr_1448_21Cited by 9 Negative / Null Result Report
Juraj Koči, Marta Novotová, Monika Sláviková et al. · 2022 · Pathogens
The coronavirus transforms the cytoplasm of susceptible cells to support virus replication. It also activates autophagy-like processes, the role of which is not well understood. Here, we studied SARS-CoV-2-infected Vero E6 cells using…
View details →DOI: 10.3390/pathogens11121535Cited by 3 Negative / Null Result Report
Itandehui Hernández-Aguilar, Luis Román Ramírez-Palacios, Consuelo Lorenzo et al. · 2024 · Therya Notes
The SARS-CoV-2 virus is the etiological agent of the 2019 coronavirus disease that caused the COVID-19 pandemic. This virus has achieved sustained transmission across human populations; however, since 2020, reverse zoonotic contagion…
View details →DOI: 10.12933/therya_notes-24-155Cited by 1 Negative / Null Result ReportOpen accessMedicine
Simson Tarigan, Gita Sekarmila, Apas et al. · 2024 · PLoS ONE
Developing intranasal vaccines against pandemics and devastating airborne infectious diseases is imperative. The superiority of intranasal vaccines over injectable systemic vaccines is evident, but developing effective intranasal vaccines presents significant challenges. Fusing a protein antigen with the catalytic domain of cholera toxin (CTA1) and the two-domain D of staphylococcal protein A (DD) has significant potential for intranasal vaccines. In this study, we constructed two fusion proteins containing CTA1, tandem repeat linear epitopes of the SARS-CoV-2 spike protein (S14P5 or S21P2), a
View details →DOI: 10.1371/journal.pone.0306153 Negative / Null Result ReportMedicine
Zember, Turkbey, Chu et al. · 2026 · Pediatric radiology
Radiologic findings associated with SARS-CoV-2 infection have been well described since its emergence. However, long-term clinical and radiologic complications of pediatric SARS-CoV-2 infection are less defined, including radiologic…
View details →DOI: 10.1007/s00247-026-06701-3 Negative / Null Result ReportOpen accessTherapeutics. Pharmacology
Mudit Agarwal, Piyush Ranjan, Upendra Baitha et al. · 2020 · Frontiers in Pharmacology
Hydroxychloroquine has gained much attention as one of the candidate drugs that can be repurposed as a prophylactic agent against SARS-CoV-2, the agent responsible for the COVID-19 pandemic. Due to high transmissibility and presence of asymptomatic carriers and presymptomatic transmission, there is need for a chemoprophylactic agent to protect the high-risk population. In this review, we dissect the currently available evidence on hydroxychloroquine prophylaxis from a clinical and pharmacological point of view. In vitro studies on Vero cells show that hydroxychloroquine effectively inhibits SA
View details →DOI: 10.3389/fphar.2020.593099 Negative / Null Result ReportOpen accessComputer applications to medicine. Medical informatics
Carolina Biliotti, Nicolò Fraccaroli, Michelangelo Puliga et al. · 2025 · Journal of Medical Internet Research
BackgroundAs the spread of the SARS-CoV-2 virus coincided with lockdown measures, it is challenging to distinguish public reactions to lockdowns from responses to COVID-19 itself. Beyond the direct impact on health, lockdowns may have worsened public sentiment toward politics and the economy or even heightened dissatisfaction with health care, imposing a significant cost on both the public and policy makers. ObjectiveThis study aims to analyze the causal effect of COVID-19 lockdown policies on various dimensions of sentiment and uncertainty, using the Italian lockdown of February 2020 as a qua
View details →DOI: 10.2196/64667 Negative / Null Result Report
Wang L, Wu S, Zeng G et al. · 2026 · Preprint
Abstract Objectives To investigate the seroconversion rate and dynamics of serum IgG antibodies following Coronavirus Disease 2019(COVID-19) vaccination in children. Methods A total of 3561 children aged 3–17 years who were hospitalized at…
View details →DOI: 10.21203/rs.3.rs-9332864/v1 